Encell Co. Ltd.
456070.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$64.58B
Close$
Share Statistics
| Market cap | $64.58 Billion |
|---|---|
| Enterprise Value | $58.57 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1482 |
| Beta | 0.27 |
| Outstanding Shares | 11,024,971 |
Return
| Return on Equity | -70.43% |
|---|---|
| Return on Assets | -35.62% |
| Return on Invested Capital | -39.06% |
Valuation & Multiples
| P/E Ratio | -3.28 |
|---|---|
| PEG | -4.9 |
| Price to Sales | 13.77 |
| Price to Book Ratio | 2.05 |
| Enterprise Value to Revenue | 14.07 |
| Enterprise Value to EBIT | -2.99 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.26 |
| Debt to Equity | 0.55 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Encell Co. Ltd.
112 employees
CEO: Hong-bae Jeon Based in Seoul, South Korea, Encell Co. Ltd., established in February 2018, focuses on the research, development, and manufacturing of biopharmaceuticals. The company offers tailored pharmaceutical development services, guiding projects from their initial concept through to regulatory approval.